- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Govt Panel Drops Plan to Ban Ads on Schedule G Drugs, Cites Alternative Approach

New Delhi: The Drug Technical Advisory Board (DTAB) has decided to withdraw the draft notification proposing a ban on advertisements of drugs listed under Schedule G of the Drugs Rules, 1945, following detailed deliberations on the matter.
The Drug Technical Advisory Board (DTAB), in its 93rd meeting held on 16 February 2026 at FDA Bhawan, Kotla Road, New Delhi in hybrid mode, deliberated on the proposal to prohibit advertisements of drugs specified under Schedule G of the Drugs Rules, 1945, and decided to withdraw the earlier draft notification on the matter.
During the deliberations, the Board was apprised of the proposal to amend the Drugs Rules, 1945 to prohibit advertisements of Schedule G drugs.
Schedule G (Cautionary Drugs)
Includes drugs that require medical supervision but are not strictly restricted to prescription-only sale.Must carry the label warning:“Caution: It is dangerous to take this preparation except under medical supervision.”These drugs can still be available without strict prescription control in some cases, but their use must be guided by a qualified practitioner.
Schedule H (Prescription Drugs)
Covers drugs that can be sold only on the prescription of a registered medical practitioner.Retail sale without a valid prescription is prohibited.Labels must display the symbol “Rx” and the warning:“Schedule H drug – Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only.”Advertising of these drugs to the general public is not permitted under existing regulations.
Board noted that DTAB in its 92nd meeting dated 24.04.2025 has already recommended that all drugs mentioned under Schedule G shall be shifted to Schedule H Drugs for better regulatory control.
DTAB after deliberation agreed with the proposal to withdraw the draft notification published vide G.S.R. 375(E) dated 10.07.2024 to prohibit the advertisements of drugs specified in Schedule G as once these drugs are shifted to Schedule H, the issue will get addressed automatically.
Mpharm (Pharmacology)
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

